Targeting B cells with biologics in systemic lupus erythematosus

Bibliography

• von Boehmer H, Melchers F. Checkpoints in lymphocyte development and autoimmune disease. Nat Immunol 2010;11:14-20
   PubMed Web of Science ®Google Scholar
• Mamula M, Fatenejad S, Craft J. B cells process and present lupus autoantigens that initiate autoimmune T cell responses. J Immunol 1994;152:1453-61
   PubMed Web of Science ®Google Scholar
• Bubien J, Zhou L, Bell P, Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993;121:1121-32
   PubMed Web of Science ®Google Scholar
• Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Investig Drugs 2008;9:1206-15
   PubMed Web of Science ®Google Scholar
• Silverman G, Weisman S. Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy. Arthritis Rheum 2003;48:1484-92
   PubMed Web of Science ®Google Scholar
• Reff M, Carner K, Chambers K, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
   PubMed Web of Science ®Google Scholar
• Looney R, Anolik J, Campbell D, B cell depletion as a novel treatment for systemic lupus erythematosus: a Phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-89
   PubMed Web of Science ®Google Scholar
• Edwards J, Szczepanski L, Szechinski J, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81
   PubMed Web of Science ®Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a Phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54:1390-400
   PubMed Web of Science ®Google Scholar
• Chambers S, Isenberg D. Anti-B cell therapy (rituximab) in the treatment of autoimmune diseases. Lupus 2005;14:210-14
   PubMed Web of Science ®Google Scholar
• Anolik J, Barnard J, Cappione A, Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum 2004;50:3580-90
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Yamamoto K, Takeuchi T, A multicenter Phase I/II trial of rituximab for refractory systemic lupus erythematosus. Mod Rheumatol 2007;17:191-97
   PubMedGoogle Scholar
• Ng K, Cambridge G, Leandro M, B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007;66:1259-62
   PubMed Web of Science ®Google Scholar
• Jonsdottir T, Gunnarsson I, Risselada A, Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008;67:1724-31
   PubMed Web of Science ®Google Scholar
• Sfikakis P, Boletis J, Tsokos G. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol 2005;17:550-7
   PubMed Web of Science ®Google Scholar
• Ng K, Leandro M, Edwards J, Repeated B cell depletion in treatment of refractory systemic lupus erythematosus. Ann Rheum Dis 2006;65:942-5
   PubMed Web of Science ®Google Scholar
• Ruckert A, Glimm H, Lubbert M, Grullich C. Successful treatment of life-threatening Evans syndrome due to antiphospholipid antibody syndrome by rituximab-based regimen: a case with long-term follow-up. Lupus 2008;17:757-60
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, Phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62:222-33
   PubMed Web of Science ®Google Scholar
• Bruce IN. Reevaluation of biologic therapies in systemic lupus erythematosus. Curr Opin Rheumatol 2010;22:273-7
   PubMed Web of Science ®Google Scholar
• Terrier B, Amoura Z, Ravaud P, Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 2010;62:2458-66
   PubMed Web of Science ®Google Scholar
• Boren E, Cheema G, Naguwa S, The emergence of progressive multifocal leukoencephalopathy (PML) in rheumatic diseases. J Autoimmun 2008;30:90-8
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Molloy ES. Therapy: rituximab and PML risk-informed decisions needed! Nat Rev Rheumatol 2009;5:528-9
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Cohen S, Pardo P, B cell depletion in subjects with controlled systemic lupus erythematosus (SLE) after intravenous or subcutaneous administration of SBI-087. Abstract SAT188, EULAR Meeting; June 2010; Rome, Italy
   Google Scholar
• Sato S, Miller A, Inaoki M, CD22 is both a positive and negative regulator of B lymphocyte antigen receptor signal transduction: altered signaling in CD22-deficient mice. Immunity 1996;5:551-62
   PubMed Web of Science ®Google Scholar
• Sato S, Tuscano J, Inaoki M, Tedder T. CD22 negatively and positively regulates signal transduction through the B lymphocyte antigen receptor. Semin Immunol 1998;10:287-97
   PubMed Web of Science ®Google Scholar
• Carnahan J, Wang P, Kendall R, Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res 2003;9:3982S-3990S
   PubMed Web of Science ®Google Scholar
• Dorner T, Kaufmann J, Wegener W, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Jacobi A, Goldenberg D, Hiepe F, Differential effects of epratuzumab on peripheral blood B cells of patients with systemic lupus erythematosus versus normal controls. Ann Rheum Dis 2008;67:450-7
   PubMed Web of Science ®Google Scholar
• Steinfeld S, Tant L, Burmester G, Epratuzumab (humanised anti-CD22 antibody) in primary Sjogren's syndrome: an open-label Phase I/II study. Arthritis Res Ther 2006;8:R129
   PubMed Web of Science ®Google Scholar
• Kalunian K, Wallace DJ, Petri M, BILAG-measured improvement in moderately and severely affected body systems in patients with systemic lupus erythematosus (SLE) by epratuzumab: results from EMBLEM™, a Phase IIb study. Abstract SAT197, EULAR Meeting; June 2010; Rome, Italy
   Google Scholar
• Gross J, Dillon S, Mudri S, TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. Impaired B cell maturation in mice lacking BLyS. Immunity 2001;15:289-302
   PubMed Web of Science ®Google Scholar
• Stohl W, Metyas S, Tan S, B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003;48:3475-86
   PubMed Web of Science ®Google Scholar
• Stohl W. SLE–systemic lupus erythematosus: a BLySful, yet BAFFling, disorder. Arthritis Res Ther 2003;5:136-8
   PubMed Web of Science ®Google Scholar
• Cambridge G, Stohl W, Leandro M, Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum 2006;54:723-32
   PubMed Web of Science ®Google Scholar
• Lavie F, Miceli-Richard C, Ittah M, Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007;66:700-3
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Heimburger M, Gunnarsson I, Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Res Ther 2006;8:R167
   PubMed Web of Science ®Google Scholar
• Adis International Limited. Belimumab: anti-BLyS human monoclonal antibody, anti-BLyS monoclonal antibody, BmAb, human monoclonal antibody to Blymphocyte stimulator. Drugs R D 2008;9:197-202
   PubMedGoogle Scholar
• Navarra S, Guzman R, Gallacher A, Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the Phase III BLISS-52 study. Abstract LB1, American College of Rheumatology Annual Meeting; October 2009; Philadelphia, PA
   Google Scholar
• Van Vollenhoven R, Zamani O, Wallace DJ, Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Abstract OP0068, EULAR Meeting; June 2010; Rome, Italy
   Google Scholar
• Lee C, Hymowitz S, Wallweber H, Synthetic anti-BR3 antibodies that mimic BAFF binding and target both human and murine B cells. Blood 2006;108:3103-11
   PubMed Web of Science ®Google Scholar
• Mackay F, Ambrose C. The TNF family members BAFF and APRIL: the growing complexity. Cytokine Growth Factor Rev 2003;14:311-24
   PubMed Web of Science ®Google Scholar